Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats

Neuropharmacology

Volumn 46, Issue 2, 2004, Pages 254-263

  Shachar, Dorit Ben ^a   Kahana, Nava ^a   Kampel, Vladimir ^a   Warshawsky, Abraham ^a   Youdim, Moussa B H ^b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

6 hydroxydopamine; Dopamine; Iron; Iron chelator VK 28; Lipid peroxidation; Mitochondria; Neurodegeneration; Neuroprotection; Nigrostriatal dopamine neurons; Serotonin

Indexed keywords

5 [4 (2 HYDROXYETHYL)PIPERAZIN 1 YLMETHYL]QUINOLIN 8 OL; DEFEROXAMINE MESYLATE; DIHYDROXYPHENYLACETIC ACID; DOPAMINE; FERROUS ASCORBATE; HOMOVANILLIC ACID; IRON CHELATING AGENT; OXIDOPAMINE; UNCLASSIFIED DRUG; VK 28;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN INJURY; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG EFFECT; DRUG SYNTHESIS; IC 50; IRON CHELATION; LIPID PEROXIDATION; MALE; MITOCHONDRIAL MEMBRANE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; STRIATE CORTEX; TREATMENT OUTCOME;

EID: 0346849912     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2003.09.005     Document Type: Article

References (77)

1. Acuna-Castroviejo D., Coto-Montes A., Gaia Monti M., Ortiz G.G., Reiter R.J. Melatonin is protective against MPTP-induced striatal and hippocampal lesions. Life Sci. 60:1997;L23-L29.
2. Ben-Shachar D., Ashkenazi R., Youdim M.B.H. Long-term consequence of early iron-deficiency on dopaminergic neurotransmission in rats. Int. J. Dev. Neurosci. 4:1986;81-88.
3. Ben-Shachar D., Riederer P., Youdim M.B.H. Iron-melanin interaction and lipid peroxidation: implications for Parkinson's disease. J. Neurochem. 57:1991;1609-1614.
4. Ben-Shachar D., Eshel G., Finberg J.P., Youdim M.B. The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J. Neurochem. 56:1991;1441-1444.
5. Berg D., Grote C., Rausch W.D., Maurer M., Wesemann W., Riederer P., Becker G. Iron accumulation in the substantia nigra in rats visualized by ultrasound. Ultrasound Med. Biol. 25:1999;901-904.
6. Borisenko G.G., Kagan V.E., Hsia C.J., Schor N.F. Interaction between 6-hydroxydopamine and transferrin: "Let my iron go" Biochemistry. 39:2000;3392-3400.
7. Cadet J.L., Katz M., Jackson-Lewis V., Fahn S. Vitamin E attenuates the toxic effects of intrastriatal injection of 6-hydroxydopamine (6-OHDA) in rats: behavioral and biochemical evidence. Brain Res. 476:1989;10-15.
8. Caraway W.T. Marco and Micro method for the determination of serum iron and iron binding capacity. Clin. Chem. 1963;188-196.
9. Cohen G. Oxidative stress, mitochondrial respiration and Parkinson's disease. Ann. NY Acad. Sci. 899:2000;112-120.
10. Dexter D.T., Wells F.R., Lees A.J., Agid F., Agid Y., Jenner P., Marsden C.D. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J. Neurochem. 52:1989;1830-1836.
11. Dexter D.T., Carter C.J., Wells F.R., Javoy-Agid F., Agid Y., Lees A., Jenner P., Marsden C.D. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J. Neurochem. 52:1989;381-389.
12. Double K.L., Maywald M., Schmittel M., Riederer P., Gerlach M. In vitro studies of ferritin iron release and neurotoxicity. J. Neurochem. 70:1998;2492-2499.
13. Eisenstein R.S. Iron regulatory proteins and the molecular control of mammalian iron metabolism. Annu. Rev. Nutr. 20:2000;627-662.
14. Ferger B., Spratt C., Teismann P., Seitz G., Kuschinsky K. Effects of cytisine on hydroxyl radicals in vitro and MPTP-induced dopamine depletion in vivo. Eur. J. Pharmacol. 360:1998;155-163.
15. Gassen M., Gross A., Youdim M.B. Apomorphine enantiomers protect cultured pheochromocytoma (PC12) cells from oxidative stress induced by H2O2 and 6-hydroxydopamine. Mov. Disord. 13:1998;242-248.
16. Gassen M., Glinka Y., Pinchasi B., Youdim M.B.H. Apomorphine is a highly potent free radical scavenger in rat brain mitochondrial fraction. Eur. J. Pharmacol. 308:1996;219-225.
17. Gerlach M., Ben-Shachar D., Riederer P., Youdim M.B.H. Altered brain metabolism of iron as a cause of neurodegenerative diseases? J. Neurochem. 793:1994;793-807.
18. Glinka Y., Tipton K.F., Youdim M.B. Nature of inhibition of mitochondrial respiratory complex I by 6-Hydroxydopamine. J. Neurochem. 66:1996;2004-2010.
19. Glinka Y., Tipton K.F., Youdim M.B.H. Mechanism of inhibition of mitochondrial respiratory complex I by 6-hydroxydopamine and its prevention by desferrioxamine. Eur. J. Pharmacol. 351:1998;121-129.
20. Glinka Y.Y., Youdim M.B. Inhibition of mitochondrial complexes I and IV by 6-hydroxydopamine. Eur. J. Pharmacol. 292:1995;329-332.
21. Goto K., Mochizuki H., Imai H., Akiyama H., Mizuno Y. An immuno-histochemical study of ferritin in 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys. Brain Res. 724:1996;125-128.
22. Grunblatt E., Mandel S., Berkuzki T., Youdim M.B.H. Apomorphine protects against MPTP-induced neurotoxicity in mice. Mov. Disord. 14:1999;612-618.
23. Grunblatt E., Mandel S., Maor G., Youdim M.B.H. Gene expression analysis in MPTP mice model of Parkinson's disease using cDNA microarray. J. Neurochem. 78:2001;1-12.
24. Grunblatt E., Mandel S., Maor G., Youdim M.B.H. Effects of R-apomorphine and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss. J. Neurochem. 77:2001;146-156.
25. Hall S., Rutledge J.N., Schallert T. MRI, brain iron and experimental Parkinson's disease. J. Neurol. Sci. 113:1992;198-208.
26. Hallgren B., Sourander P. The effect of age on the nonhaem iron in the human brain. J. Neurochem. 1958;41.
27. Halliwell B. Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging. 18:2001;685-716.
28. Han J., Cheng F.C., Yang Z., Dryhurst G. Inhibitors of mitochondrial respiration, iron (II), and hydroxyl radical evoke release and extracellular hydrolysis of glutathione in rat striatum and substantia nigra: potential implications to Parkinson's disease. J. Neurochem. 73:1999;1683-1695.
29. Hunot S., Brugg B., Ricard D., Michel P.P., Muriel M.P., Ruberg M., Faucheux B.A., Agid Y., Hirsch E.C. Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with Parkinson's disease. Proc. Natl. Acad. Sci. USA. 94:1997;7531-7536.
30. Itazaki H., Kawasaki A., Matsuura M., Ueda M., Yonetani Y., Nakamura M. Synthesis of 2,3-dihydro-1,4-benzodioxin derivatives. I. 2-substituted- 5(and 6)-sulfamoyl-2,3-dihydro-1,4-benzodioxins. Chem. Pharm. Bull. (Tokyo). 36:1988;3387-3403.
31. Jellinger K., Paulus W., Grundke-Iqbal I., Riederer P., Youdim M.B.H. Brain iron and ferritin in Parkinson's and Alzheimer's diseases. J. Neural. Transm. Park Dis. Dement. Sect. 2:1990;327-340.
32. Jellinger K., Kienzel E., Rumpelmair G., Riederer P., Stachelberger H., Ben-Shachar D., Youdim M.B.H. Iron-melanin complex in substantia nigra of parkinsonian brains: an x-ray microanalysis. J. Neurochem. 59:1992;1168-1171.
33. Jellinger K.A. The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease. Drugs Aging. 14:1999;115-140.
34. Jenner P., Olanow C.W. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology. 47:1996;S161-S170.
35. Kaur D., Yantiri F., Rajagopalan S., Kumar J., Mo J.Q., Boonplueang R., Viswanath V., Jacobs R., Yang L., Beal M.F., DiMonte D., Volitaskis I., Ellerby L., Cherny R.A., Bush A.I., Andersen J.K. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 27. 37:(6):2003;899-909.
36. Lan J., Jiang D.H. Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice. J. Neural. Transm. (Budapest). 104:1997;469-481.
37. Lan J., Jiang D.H. Excessive iron accumulation in the brain: a possible potential risk of neurodegeneration in Parkinson's disease. J. Neural. Transm. 104:1997;649-660.
38. Langston J.W. The etiology of Parkinson's disease with emphasis on the MPTP story. Neurology. 47:1996;S153-S160.
39. LaVaute T., Smith S., Cooperman S., Iwai K., Land W., Meyron-Holtz E., Drake S.K., Miller G., Abu-Asab M., Tsokos M., Switzer R. III, Grinberg A., Love P., Tresser N., Rouault T.A. Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice. Nat. Genet. 27:2001;209-214.
40. Leibold E.A., Gahring L.C., Rogers S.W. Immunolocalization of iron regulatory protein expression in the murine central nervous system. Histochem. Cell Biol. 115:2001;195-203.
41. Levenson, C.W., Perkov B. and Matteson A., 2003. Effect of dietary iron deficiency on motor behaviour and neuronal death in an experimental model of Parkinsoism. Journal of American Aging Association, (in press).
42. Levites Y., Youdim M.B.H., Maor G., Mandel S. Attenuation of 6-hydroxydopamine (6-OHDA)-induced nuclear factor-kappaB (NF-kappaB) activation and cell death by tea extracts in neuronal cultures. Biochem. Pharmacol. 63:2002;21-29.
43. Levites Y., Weinreb O., Maor G., Youdim M.B.H., Mandel S. Green tea polyphenol (-)- Epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced dopaminergic neurodegeneration. J. Neurochem. 78:2001;1073-1082.
44. Lin M., Rippe R.A., Niemela O., Brittenham G., Tsukamoto H. Role of iron in NF-kappa B activation and cytokine gene expression by rat hepatic macrophages. Am. J. Physiol. 272:1997;G1355-G1364.
45. Lin Y.L., Lin J.K. (-)-Epigallocatechin-3-gallate blocks the induction of nitric oxide synthase by down-regulating lipopolysaccharide-induced activity of transcription factor nuclear factor-kappaB. Mol. Pharmacol. 52:1997;465-472.
46. Linert W., Herlinger E., Jameson R.F., Kienzl E., Jellinger K., Youdim M.B.H. Dopamine, 6-hydroxydopamine, iron, and dioxygen- - their mutual interactions and possible implication in the development of Parkinson's disease. Biochim. Biophys. Acta. 1316:1996;160-168.
47. Lode H.N., Bruchelt G., Rieth A.G., Niethammer D. Release of iron from ferritin by 6-hydroxydopamine under aerobic and anaerobic conditions. Free Radic. Res. Commun. 11:1990;153-158.
48. Mandel S., Grunblatt E., Levites Y., Maor G., Youdim M.B.H. Genes and oxidative stress in parkinsonism; cDNA microarray studies. Adv. Neurol. 91:2003;123-132.
49. Mash D.C., Pablo J., Buck B.E., Sanchez-Ramos J., Weiner W.J. Distribution and number of transferrin receptors in Parkinson's disease and in MPTP-treated mice. Exp. Neurol. 114:1991;73-81.
50. Miyajima H., Takahashi Y., Kamata T., Shimizu H., Sakai N., Gitlin J.D. Use of desferrioxamine in the treatment of aceruloplasminemia. Annal. Neurol. 41:1997;404-407.
51. Mochizuki H., Imai H., Endo K., Yokomizo K., Murata Y., Hattori N., Mizuno Y. Iron accumulation in the substantia nigra of 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine (MPTP)-induced hemiparkinsonian monkeys. Neurosci. Lett. 168:1994;251-253.
52. Monteiro H.P., Winterbourn C.C. 6-Hydroxydopamine releases iron from ferritin and promotes ferritin-dependent lipid peroxidation. Biochem. Pharmacol. 38:1989;4177-4182.
53. Moussaoui S., Obinu M.C., Daniel N., Reibaud M., Blanchard V., Imperato A. The antioxidant ebselen prevents neurotoxicity and clinical symptoms in a primate model of Parkinson's disease. Exp. Neurol. 166:2000;235-245.
54. Nagatsu T., Mogi M., Ichinose H., Togari A. Cytokines in Parkinson's disease. J. Neural. Transm. Suppl. 58:2002;143-151.
55. Oestreicher E., Sengstock G.J., Riederer P., Olanow C.W., Dunn A.J., Arendash G.W. Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study. Brain Res. 660:1994;8-18.
56. Paxinos G., Watson C. The rat brain in stereotaxic coordinates. 1982;Academic Press, New York.
57. Perry T.L., Yong V.W., Clavier R.M., Jones K., Wright J.M., Foulks J.G., Wall R.A. Partial protection from the dopaminergic neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by four different antioxidants in the mouse. Neurosci. Lett. 60:1985;109-114.
58. Pezzella A., d'Ischia M., Napolitano A., Misuraca G., Prota G. Iron-mediated generation of the neurotoxin 6-hydroxydopamine quinone by reaction of fatty acid hydroperoxides with dopamine: a possible contributory mechanism for neuronal degeneration in Parkinson's disease. J. Med. Chem. 40:1997;2211-2216.
59. Ramsay R.R., Kowal A.T., Johnson M.K., Salach J.I., Singer T.P. The inhibition site of MPP+, the neurotoxic bioactivation product of 1- methyl-4-phenyl-1,2,3,6-tetrahydropyridine is near the Q-binding site of NADH dehydrogenase. Arch. Biochem. Biophys. 259:1987;645-649.
60. Rehncrona S., Smith D.S., Akesson B., Westerberg E., Siesjo B.K. Peroxidative changes in brain cortical fatty acids and phospholipids, as characterized during Fe2+- and ascorbic acid-stimulated lipid peroxidation in vitro. J. Neurochem. 34:1980;1630-1638.
61. Riederer P., Sofic E., Rausch W.D., Schmidt B., Reynolds G.P., Jellinger K., Youdim M.B.H. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem. 52:1989;515-520.
62. Roghani M., Behzadi G. Neuroprotective effect of vitamin E on the early model of Parkinson's disease in rat: behavioral and histochemical evidence. Brain Res. 892:2001;211-217.
63. Seaton T.A., Cooper J.M., Schapira A.H. Free radical scavengers protect dopaminergic cell lines from apoptosis induced by complex I inhibitors. Brain Res. 777:1997;110-118.
64. Shoham S., Youdim M.B.H. Iron involvement in neural damage and microgliosis in models of neurodegenerative diseases. Cell Mol. Biol. 46:2000;743-760.
65. Sofic E., Riederer P., Heinsen H., Beckmann H., Reynolds G.P., Hebenstreit G., Youdim M.B.H. Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J. Neural Transm. 74:1988;199-205.
66. Temlett J.A., Landsberg J.P., Watt F., Grime G.W. Increased iron in the substantia nigra compacta of the MPTP-lesioned hemiparkinsonian African green monkey: evidence from proton microprobe elemental microanalysis. J. Neurochem. 62:1994;134-146.
67. Tominaga M., Yo E., Ogawa H., Yamashita S., Yabuuchi Y., Nakagawa K. Studies on positive inotropic agents. II. Synthesis of (4-substituted 1- piperazinylcarbonyl)-2-(1H)-quinolinone derivatives. Chem. Pharm. Bull. (Tokyo). 34:1986;682-693.
68. Tsukamoto H., Lin M., Ohata M., Giulivi C., French S.W., Brittenham G. Iron primes hepatic macrophages for NF-kappaB activation in alcoholic liver injury. Am. J. Physiol. 277:1999;G1240-G1250.
69. Ungerstedt U. 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur. J. Pharmacol. 5:1968;107-110.
70. Uretsky N.J., Iversen L.L. Effects of 6-hydroxydopamine on catecholamine containing neurones in the rat brain. J. Neurochem. 17:1970;269-278.
71. Warshawsky, B., Ben-Shachar, D., Youdim, M.B.H., 2000. Pharmaceutical compositions comprising iron chelators for the treatment of neurodegenerative disorders and some novel iron chelators. International application published under the patent cooperationtreaty. International Publication Number WO 00/ 74664 A2.
72. Weinfeld A. Storage iron in man. Acta Medica Scandinavia Suppl. 177:1964;1-29.
73. Youdim M.B., Ben-Shachar D., Riederer P. The possible role of iron in the etiopathology of Parkinson's disease. Mov. Disord. 8:1993;1-12.
74. Youdim, M.B.H., 1985. Brain iron metabolism. biochemical and behavioral aspects in relation to dopaminergic neurotransmission. In: Handbook of Neurochemistry. Plenum, New York.
75. Youdim, M.B.H., Riederer, P., 2003. Iron in the brain, normal and pathological.conditions. In: Smith, B., Adelman, G. (Eds.), Encyclopedia of Neuroscience. Elsevier, Amsterdam (in press).
76. Youdim M.B.H., Grunblatt E., Mandel S. The pivotal role of iron in NF-kappa B activation and nigrostriatal dopaminergic neurodegeneration. Prospects for neuroprotection in Parkinson's disease with iron chelators. Ann. NY Acad. Sci. 890:1999;7-25.
77. Youdim, M.B.H., Eshel, G., Ben-Shachar D., 2003. Ironing out iron from Parkinson's disease and other neurodegenerative diseases with iron chelators; A lesson from 6-hydroxydopamine and iron chelators desferal and VK-28. Ann. NY Acad. Sci. (In press).